Is Anika Therapeutics Stock a Good Investment?
Anika Therapeutics Investment Advice | ANIK |
- Examine Anika Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Anika Therapeutics' leadership team and their track record. Good management can help Anika Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Anika Therapeutics' business and its evolving consumer preferences.
- Compare Anika Therapeutics' performance and market position to its competitors. Analyze how Anika Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Anika Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Anika Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Anika Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Anika Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Anika Therapeutics Stock
Researching Anika Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 90.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. Anika Therapeutics recorded a loss per share of 0.6. The entity had not issued any dividends in recent years.
To determine if Anika Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Anika Therapeutics' research are outlined below:
| Anika Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 119.91 M. Net Loss for the year was (56.38 M) with profit before overhead, payroll, taxes, and interest of 76.6 M. | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from aol.com: Quinta Brunson files to divorce husband Kevin Anik after three years of marriage |
Anika Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Anika Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Anika Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Anika Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Anika Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
1999-10-21 | 1999-09-30 | 0.01 | 4.0E-4 | -0.0096 | 96 | ||
2008-07-22 | 2008-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2021-03-04 | 2020-12-31 | 0.14 | 0.12 | -0.02 | 14 | ||
2007-02-28 | 2006-12-31 | 0.11 | 0.09 | -0.02 | 18 | ||
2005-07-27 | 2005-06-30 | 0.1 | 0.12 | 0.02 | 20 | ||
2005-04-27 | 2005-03-31 | 0.08 | 0.1 | 0.02 | 25 | ||
2004-10-29 | 2004-09-30 | 0.06 | 0.08 | 0.02 | 33 | ||
2004-08-06 | 2004-06-30 | 0.05 | 0.07 | 0.02 | 40 |
Anika Therapeutics Target Price Consensus
Anika target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Anika Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Anika analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Anika stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Anika Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAnika Therapeutics Target Price Projection
Anika Therapeutics' current and average target prices are 15.47 and 26.50, respectively. The current price of Anika Therapeutics is the price at which Anika Therapeutics is currently trading. On the other hand, Anika Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Anika Therapeutics Market Quote on 24th of March 2025
Target Price
Analyst Consensus On Anika Therapeutics Target Price
Anika Therapeutics Analyst Ratings
Anika Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Anika Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Anika Therapeutics' financials, market performance, and future outlook by experienced professionals. Anika Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Anika Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Anika Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anika Therapeutics backward and forwards among themselves. Anika Therapeutics' institutional investor refers to the entity that pools money to purchase Anika Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stonepine Capital Management Llc | 2024-12-31 | 238.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 189.2 K | Meros Investment Management, Lp | 2024-12-31 | 177.7 K | D. E. Shaw & Co Lp | 2024-12-31 | 153.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 137.5 K | Northern Trust Corp | 2024-12-31 | 123.2 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 119 K | Globeflex Capital, L.p. | 2024-12-31 | 87.6 K | Jpmorgan Chase & Co | 2024-12-31 | 82.5 K | Trigran Investments Inc | 2024-12-31 | 2 M | Blackrock Inc | 2024-12-31 | 1.6 M |
Anika Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 218.59 M.Market Cap |
|
Anika Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.28) | |
| Return On Capital Employed | (0.03) | (0.03) | |
| Return On Assets | (0.28) | (0.26) | |
| Return On Equity | (0.37) | (0.35) |
Determining Anika Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Anika Therapeutics is a good buy. For example, gross profit margin measures Anika Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Anika Therapeutics' profitability and make more informed investment decisions.
Anika Therapeutics' Earnings Breakdown by Geography
Evaluate Anika Therapeutics' management efficiency
Anika Therapeutics has return on total asset (ROA) of (0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0482) %, meaning that it created substantial loss on money invested by shareholders. Anika Therapeutics' management efficiency ratios could be used to measure how well Anika Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.28 this year. Return On Capital Employed is expected to rise to -0.03 this year. Change To Liabilities is expected to rise to about 3.6 M this year, although the value of Total Current Liabilities will most likely fall to about 12.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.46 | 6.69 | |
| Tangible Book Value Per Share | 9.81 | 5.66 | |
| Enterprise Value Over EBITDA | (41.68) | (39.60) | |
| Price Book Value Ratio | 1.57 | 1.71 | |
| Enterprise Value Multiple | (41.68) | (39.60) | |
| Price Fair Value | 1.57 | 1.71 | |
| Enterprise Value | 511.9 M | 537.5 M |
The operational strategies employed by Anika Therapeutics management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.95 |
Basic technical analysis of Anika Stock
As of the 24th of March, Anika Therapeutics shows the Risk Adjusted Performance of (0.05), standard deviation of 2.1, and Mean Deviation of 1.44. Anika Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Anika Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anika Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anika Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anika Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anika Therapeutics' Outstanding Corporate Bonds
Anika Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Anika Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Anika bonds can be classified according to their maturity, which is the date when Anika Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ANHEUSER BUSCH INBEV FIN Corp BondUS035242AN64 | View | |
| ANHEUSER BUSCH INBEV FIN Corp BondUS035242AM81 | View | |
| ANHEUSER BUSCH INBEV FIN Corp BondUS035242AB27 | View | |
| US035229BP76 Corp BondUS035229BP76 | View | |
| US035229BQ59 Corp BondUS035229BQ59 | View | |
| ANHEUSER BUSCH PANIES LLC Corp BondUS03522AAJ97 | View | |
| ANHEUSER BUSCH LLC ANHEUSER Corp BondUS03522AAG58 | View |
Understand Anika Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Anika Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 1.44 | |||
| Coefficient Of Variation | (1,510) | |||
| Standard Deviation | 2.1 | |||
| Variance | 4.43 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.0104 | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 14.35 | |||
| Value At Risk | (2.32) | |||
| Potential Upside | 2.68 | |||
| Skewness | (1.95) | |||
| Kurtosis | 10.38 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 1.44 | |||
| Coefficient Of Variation | (1,510) | |||
| Standard Deviation | 2.1 | |||
| Variance | 4.43 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.0104 | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 14.35 | |||
| Value At Risk | (2.32) | |||
| Potential Upside | 2.68 | |||
| Skewness | (1.95) | |||
| Kurtosis | 10.38 |
Consider Anika Therapeutics' intraday indicators
Anika Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Anika Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Anika Therapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 17th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 12th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of February 2025 Other Reports | ViewVerify |
Anika Stock media impact
Far too much social signal, news, headlines, and media speculation about Anika Therapeutics that are available to investors today. That information is available publicly through Anika media outlets and privately through word of mouth or via Anika internal channels. However, regardless of the origin, that massive amount of Anika data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Anika Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Anika Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Anika Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Anika Therapeutics alpha.
Anika Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Anika Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Anika Therapeutics Corporate Management
| Ian McLeod | VP Officer | Profile | |
| James Chase | Senior Marketing | Profile | |
| Bart Bracy | VP Americas | Profile | |
| Lisa Funiciello | Vice Resources | Profile | |
| Mark Namaroff | Executive Communications | Profile | |
| Michael CPA | Executive Officer | Profile | |
| Charles III | VP Counsel | Profile |
Already Invested in Anika Therapeutics?
The danger of trading Anika Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Anika Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Anika Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Anika Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (0.60) | Revenue Per Share | Quarterly Revenue Growth (0.29) | Return On Assets |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Anika Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.